Prevention of infection after TAC chemotherapy for node-positive breast cancer as an adjuvant therapy with or without ciprofloxacin

613 Background: TAC (docetaxel, doxorubicin and cyclophosphamide) chemotherapy has been accepted as an adjuvant chemotherapy for the node positive breast cancer. But, moderate to severe adverse reactions, especially neutropenia, right after this regimen have been major hurdle for the wider enthusiasm. Until now, ciprofloxacin has been given to patients on completion of each cycle to prevent systemic infection. We tried to determine if ciprofloxacin is to be included in the post-chemotherapy medications or not to stop possible infection. Methods: We randomly assigned 100 patients into two groups between Jan. 2006 to Oct. 2007. Study group (A; n=50 patients, 300 cycles) was given prophylactic G-CSF (300 ug) from day 5 to day 10, and the control group (B; n=50, 300 cycles) was given G-CSF and ciprofloxacin (500 mg, orally twice daily) from day 5 to 10. We compared the incidence of infection and neutropenia prospectively. This study was reviewed by the IRB and informed consent from the patient should be compu...